ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 699

Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes

Nimrit Dhillon1, Dominique Ibanez1, Dafna D. Gladman2 and Murray B. Urowitz2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: avascular necrosis and osteonecrosis, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE).  The reported frequency of symptomatic osteonecrosis in SLE is variable, ranging from 4% to 15%. 

The aim of this study is to provide an update of the prevalence, patterns and outcomes of symptomatic osteonecrosis in SLE. 

Methods:

SLE patients with osteonecrosis were identified from the Lupus Clinic Database containing patients with 4 ACR criteria of SLE or 3 criteria and a biopsy diagnostic of lupus.  Osteonecrosis was defined as those patients with clinical symptoms and confirmed osteonecrosis by imaging (x-ray, bone scan, CT, MRI).  Demographic and clinical data of affected patients were collected prospectively, stored in an Oracle database and analyzed using descriptive statistics. 

Results:

Of the 1729 patients with SLE registered in the database as of 1970, 235 patients (13.6%) developed symptomatic osteonecrosis.  86.0% were female, with a mean age of 34.8 ± 12.8 years at first osteonecrosis diagnosis.  This involved a total of 542 joints, 383 joints of which were identified at the time of first osteonecrosis occurrence.  The mean time from diagnosis of SLE to diagnosis of first osteonecrosis was 8.2 ± 8.1 years, and the time from first osteonecrosis diagnosis to second osteonecrosis diagnosis was 3.4 ± 4.8 years. 

111 out of 235 (47%) patients had multiple site involvement at first osteonecrosis occurrence, affecting from 2 to 6 sites.  At the time of first diagnosis affected sites included the hip (245), knee (86), shoulder (28), ankle (15), wrist (3), other joints (3) and elbow (2).   Those that progressed to surgical intervention included: hip 131/245 (53.5%), knee 18/86 (19.8%), wrist 1/3 (33.3%), shoulder 1/28 (3.6%), ankle 0/15 (0%), elbow 0/2 (0%), and other joints 1/3 (33%).  The mean time from osteonecrosis diagnosis to surgery of the hip was 3.8 ± 5.5 years, while the mean time from osteonecrosis diagnosis to surgery of the knee was 5.5 ± 6.2 years.

Conclusion:

To our knowledge, this is the largest cohort of SLE patients with symptomatic osteonecrosis.  Osteonecrosis continues to be a significant comorbidity of SLE as 13.6% of patients developed symptomatic osteonecrosis.  In patients developing osteonecrosis, the presentation occurred after 8.2 ± 8.1 years of SLE disease duration.  47.2% of patients had multiple site involvement at first ON diagnosis.  Large weight-bearing joints, including the hip and knee, were most frequently involved.  The majority of hips required surgical intervention. Better strategies to prevent this serious complication are needed.


Disclosure:

N. Dhillon,
None;

D. Ibanez,
None;

D. D. Gladman,
None;

M. B. Urowitz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteonecrosis-in-systemic-lupus-erythematosus-prevalence-patterns-and-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology